A phase 2, open-label, single-arm clinical trial of the safety and efficacy of the JAK1/3 inhibitor tofacitinib in Down syndrome

Chinese General Practice Journal · Elsevier

Аннотация

Publication date: 17 November 2026 Source: Cell Reports Medicine, Volume 7, Issue 11 Author(s): Angela L. Rachubinski, Emily Gurnee, Elizabeth B. Wallace, Belinda A. Enriquez Estrada, Kayleigh R. Worek, Rachel M. Shropshire, Bellina P. Guerra, Sitlali Flores Garcia, Pamela Navarette, Keith P. Smith, Ross E. Granrath, Brian F. Niemeyer, Eleanor C. Britton, Hannah R. Lyford, Madelaine Hipp, Ashley Snell, Neetha P. Eduthan, Micah G. Donovan, Kaylyn Van Deusen, Linda K. Roan

Читать у издателя →

Похожие статьи